Q-omics provides the consensus-scored SOX9 profile across patient tissues and cancer cell-line models. SOX9 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SOX9 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, SOX9 RNA expression shows 17,524 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where SOX9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX9 survival associations across molecular data types. SOX9 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX9 RNA expression–survival associations across cancer types. High SOX9 expression shows unfavorable associations in LGG, LUAD, BLCA and SKCM, but favorable associations in ACC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SOX9 RNA expression.
This table summarizes SOX9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SOX9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX9 shows higher tumor expression in COAD, STAD, LUSC, LIHC, HNSC and KIRP. The COAD box plot shows higher SOX9 RNA expression in tumor versus normal tissue (log2 FC = +2.599, t-test p < 0.001).
This table shows molecular features associated with SOX9 in patient tissues and cancer cell lines. In patient samples, SOX9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
